Lombriareu (Pyrantel Pamoate) is a medication commonly used to address specific infections caused by intestinal parasitic worms and contributes to easing the associated symptomatic burden.

Pyrantel is primarily an anti-worm medication applied in managing infections like Pinworm (Enterobiasis), Roundworm (Ascariasis), and certain Hookworm species.

---

Main Uses and Therapeutic Benefits

This medication is generally used across conditions characterized by periods of heightened symptoms for the management of the condition. Its use assists in easing distressing symptom clusters related to physical discomfort. This includes intense perianal pruritus (anal itching) that may interfere with daily functioning like sleep, and general gastrointestinal discomfort. Its use supports the patient during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.

In clinical scenarios, Lombriareu is commonly used to manage contagious spread, particularly when a case of pinworm is confirmed, necessitating a whole-household treatment approach. This supportive strategy helps to interrupt the cycle of transmission and supports against reinfection.

---

Quick Fact: Relief for Physical Discomfort
Lombriareu is relevant for easing symptoms that cluster into patterns requiring supportive management, supports the goal of parasitic management to help address the source of discomfort.

---

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Lombriareu — official regulatory information

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed	Adults and children 2 years of age and older.
Populations for whom use is contraindicated	Individuals with known Hypersensitivity to the drug or any of its components.
Use not established	Children younger than 2 years old (or under 25 pounds).

Age- and Condition-Specific Rules

Official labeling establishes a clear minimum age threshold, authorizing standard use only for individuals who are 2 years of age or older. For those under this age, the medicine is not recommended unless directed by a physician, as safety and efficacy have not been established in this pediatric group.

Use is restricted and requires mandatory physician consultation for certain health conditions or physiological states. Specifically, patients with Hepatic Disease or pre-existing Liver Dysfunction must not take this product without medical supervision. Use is also restricted for pregnant women, where the drug's status (Pregnancy Category C) requires that potential benefit must justify potential risk. Caution is also advised in patients with conditions like Anemia or Malnutrition. While excretion into human milk is unknown, use during lactation is generally considered compatible due to the drug’s minimal absorption.

Interactions with other medicines and products

The interaction profile for Lombriareu (Pyrantel Pamoate) is structured by specific restrictions and alterations observed when co-administered with other substances, as detailed in governmental regulatory information.

Documented Interaction Restrictions and Alterations

Substance / Category	Official Interaction Statement	Basis of Interaction
Piperazine	Co-administration is formally prohibited or strongly advised against in regulatory documents.	Pharmacodynamic antagonism (opposing effects on the target parasite).
Theophylline	Co-administration results in increased plasma concentration (serum levels) of Theophylline.	Pharmacokinetic exposure modification.
Food, Milk, Fruit Juice	No documented interaction; administration may occur with or without meals at any time of day.	Non-Interaction Pattern.
Alcohol	Co-consumption may potentially elevate the risk of experiencing dizziness or central nervous system (CNS) effects, as noted in official safety information.	Substance co-consumption constraint.

Official Interaction Summary

The drug's regulatory profile includes a mandatory prohibition on combination with the anthelmintic medicine Piperazine, which is classified as a contraindicated combination due to documented antagonism of effects. Separately, the official information notes a clinically significant interaction where Pyrantel alters the exposure of Theophylline, resulting in a noted increase in the co-administered drug's serum levels. The labeling explicitly confirms the absence of timing constraints relative to food, milk, or fruit juice administration. These official statements define the specific interaction structure for Lombriareu.

Targeted Agonism: Induction of Parasitic Spastic Paralysis

Lombriareu, containing Pyrantel, exerts its effect by acting as an agonist on the Nicotinic Acetylcholine Receptors ( nAChRs) located on the muscle cell membranes of susceptible parasitic worms. This binding causes continuous stimulation, which prevents the muscle from repolarizing. This sustained excitation leads directly to the core physiological effect: rigid, uncontrolled spastic paralysis of the nematode musculature.

---

Mechanistic Consequence: Loss of Anchor and Passage

The induced spastic paralysis disrupts the worm's ability to maintain muscle tone and counter the force of the host's intestinal movements. This functional loss of physical anchor allows the host's normal peristalsis (gut motility) to move the paralyzed parasite along the intestinal tract. The mechanism operates only within the lumen (lumen-restricted action) and is functionally confined to the neuromuscular system of the motile worms; it exerts no effect on the parasitic ova (eggs).

How to Use Lombriareu: Administration Guidelines

Lombriareu, which contains the active ingredient Pyrantel Pamoate, is administered exclusively via the oral route. The product is available in two main forms for ingestion: an oral suspension and chewable tablets.

---

Standard Dosing and Frequency

The standard dose is determined by the patient's body weight, set at 11 milligrams of pyrantel base per kilogram of body weight (11 mg/kg). The total dose administered must not exceed a maximum limit of 1 gram (1,000 mg) for a single treatment.

Treatment often follows a single-dose pattern for the primary clearance of the target parasite. For common infections like Pinworm, the treatment typically involves the single dose being repeated after 14 days to address the parasite's full life cycle. For certain other infections, an alternative regimen involves administering the dose once daily for three consecutive days.

---

Administration Context and Preparation

This medication is designed for flexible intake and may be taken with or without food, milk, or fruit juice. No pre-treatment fasting or the use of laxatives is necessary to facilitate its use.

Before administration, the oral suspension must be shaken thoroughly to ensure uniform drug concentration. Tablets are intended to be chewed well before swallowing. Furthermore, in cases of confirmed Pinworm infection, clinical practice often includes all members of the immediate household receiving treatment simultaneously to interrupt the cycle of transmission.

Research Evidence / Overview of Studies for Lombriareu

The evidence base for Lombriareu (Pyrantel Pamoate) focuses on its targeted evaluation against specific parasitic infections. The research, derived from Randomized Controlled Trials (RCTs) and systematic reviews, describes short-term patterns observed in formal study settings. Findings describe group patterns, not individual predictions.

---

Evidence by Indication

Research evaluating Lombriareu for pinworm infection (Enterobius vermicularis) was studied for its potential to assess parasite levels and changes in physical discomfort. Studies monitored Parasite Level Endpoints and often incorporated a second observation period at a specific interval to factor in the possibility of re-infection.

The evidence base for roundworm infection (Ascaris lumbricoides) relies on numerous RCTs and meta-analyses. These studies focused heavily on parasitological efficacy endpoints, measuring parasite level reduction and clearance endpoints across primarily single-dose regimens.

The evidence base for hookworm infection was studied for use against certain species. Research examined the effect of the medicine administered as a single dose, but trial findings frequently described how measurements varied when the medicine was evaluated in a multi-day course versus a single-day regimen.

---

Research Gaps and Uncertainties

The evidence base is focused on short-term efficacy, meaning follow-up durations were limited in many core studies. Long-term effects are not fully established regarding the sustained absence of infection. Research data for certain groups remain insufficient; specifically, few data are available for its use in children younger than 2 years of age. While studies contribute to understanding symptom patterns, evidence quality varies and certainty remains low for certain applications.

Key Studies & References

1. Pyrantel Pamoate: NIH MedlinePlus overview
2. Systematic review on the efficacy of the anthelminthic drugs currently recommended by WHO against soil-transmitted helminths (PLoS Negl Trop Dis.)

Common questions about Lombriareu (FAQ)

Q: Is Lombriareu considered a long-term or short-term medication?

Official product information describes Lombriareu as a short-duration treatment. Official information describes short-duration regimens, typically involving a single dose or a short course. For certain infections like pinworm, the protocol may require repeating the full dose after a period of approximately two weeks.

Q: Is Lombriareu a generic medication or a brand name?

The medication known as Lombriareu contains the active substance Pyrantel Pamoate. This active ingredient is an anthelmintic agent that is available over-the-counter and is marketed under various brand names, as well as in generic forms.

Q: Is it okay to take Lombriareu every day?

Regulatory guidance indicates this medication is not intended for chronic or daily use. It is administered as a short course or a single dose, and treatment should not be repeated without professional guidance.

Q: What kind of warnings are listed on the official label for Lombriareu?

Official warnings focus on specific health conditions and demographics. Restrictions are listed for individuals with known hypersensitivity to the drug and for those with pre-existing liver disease. Official information advises consulting a healthcare provider if there are plans for pregnancy, if pregnant, or while breastfeeding.

Q: Is Lombriareu safe for use by people over 65?

Official information indicates that the drug is approved for general adult use. However, official information suggests a professional health assessment is warranted for older adults, particularly those with conditions such as impaired liver function, before use.

Q: Is it safe to consume alcohol while taking Lombriareu?

Official safety information indicates that consuming alcohol while taking the medication may increase the risk of experiencing certain central nervous system (CNS) effects. These effects can include dizziness.

Q: Has there been research on Lombriareu's use in children or adolescents?

The drug's safety and efficacy are established for children aged 2 years and older. However, regulatory documents state that use is not established for children younger than 2 years old (or under 25 pounds).

Q: How does Lombriareu affect the ability to drive or operate heavy machinery?

Official warnings state that caution should be exercised because side effects, such as dizziness and drowsiness, could potentially impair physical reactions and judgment. Given these potential effects, regulatory guidance suggests refraining from hazardous activities like driving until the patient understands the drug's effect.

Q: Is there a recommended time of day for taking Lombriareu?

Regulatory documents confirm that there is no specific recommended time of day for taking the medication. It is designed to be taken flexibly, with or without meals, milk, or fruit juice.

Q: Do patients need special monitoring or blood tests while taking Lombriareu?

Routine monitoring is not typically required for all patients taking this short-duration medication. However, official reports have indicated transient elevations of liver enzymes (like AST and ALT) in some blood tests.

Q: Is Lombriareu used to treat symptoms, or does it target the underlying cause of the condition?

The medication is classified as an anthelmintic agent, meaning its primary action is to target the underlying cause. It works by paralyzing the parasitic worms, which enables their expulsion and clearance from the body.

Q: Is Lombriareu considered a controlled substance?

No. According to authoritative regulatory classification, the drug Pyrantel Pamoate is an Antinematodal Agent. It is commonly available over-the-counter in many jurisdictions and is not scheduled as a federally controlled substance.

Q: What should a patient do if they miss a scheduled dose of Lombriareu?

If a patient is on a repeat-dose regimen and realizes a dose was missed near the time of the next dose, the missed dose should be skipped. Official guidance states that a double dose should not be administered to compensate for a missed one.

Q: What are the possible signs of a severe or serious side effect from Lombriareu?

Signs of a serious adverse reaction include severe stomach pain, profound vomiting, slurred speech, or swelling of the face, throat, or tongue. If any of these symptoms or signs of a severe allergic reaction, such as hives or difficulty breathing, occur, seeking immediate medical attention is advised by official sources.

Q: What are the guidelines for discontinuing Lombriareu use?

Due to the medication's short-duration use (single dose or 3-day course), there are no complex discontinuation guidelines. The official information notes that treatment should not be repeated unless specifically advised by a healthcare professional.

How to Store and Dispose of Lombriareu (Pyrantel Pamoate)

The official instructions for storing and disposing of Lombriareu are based on regulatory labeling requirements.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection	The product must be protected from freezing.
Container	Keep the oral suspension bottle tightly closed.
Child Safety	Keep this and all medication out of the reach of children.

Disposal Instructions

Unused or expired Lombriareu must be properly discarded, preferably through a drug take-back program. It is prohibited to flush the medication down the toilet or pour it into a drain unless specifically instructed. If a take-back program is unavailable, follow the guidance for securing liquid medication (suspension) in household trash.